Full Press Release Details
Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
Limited (Scrip Code: 500124)
York Stock Exchange Inc. (Stock Code: RDY)
IFSC Ltd. (Stock Code: DRREDDY)
Appointment of an Additional Director, categorized as Independent
to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"),
we would like to inform you that Dr. Alpna Hansraj Seth (DIN: 01183914) has been appointed as an Additional Director, categorized as
Independent, on the Board of Dr. Reddy's Laboratories Ltd., for a term of five consecutive years, effective from September 19, 2023.
Her appointment is approved by the Board of Directors of the Company, by way of Circular Resolution passed today, i.e. on September 19,
2023, based on recommendations of the Nomination, Governance and Compensation Committee and is subject to approval of shareholders through
postal ballot process. The profile of Dr. Alpna is enclosed with this intimation.
Alpna Hansraj Seth is not related to any of the Director or Key Managerial Personnel of the Company and is not debarred from holding
the office of Director by virtue of any SEBI order or any other such authority. She meets the criteria for being appointed as an Independent
Director under all statutes applicable to the Company.
details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September
9, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above appointment of Dr. Alpna Hansraj Seth
is given in Annexure enclosed herewith.
is for your information and record.
Dr. Reddy's Laboratories Limited
Secretary, Compliance Officer & Head-CSR
under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015
dated September 9, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
| Sl. No. | Particulars | Details |
| 1 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise | Appointment |
| 2 | Date of appointment / re-appointment/ cessation (as applicable); and term of appointment/ re-appointment | September 19, 2023 Appointment by the Board of Directors on September 19, 2023 as an Additional Director, categorized as Independent, for a term of five consecutive years, with effect from September 19, 2023, to September 18, 2028. The said appointment is subject to approval of the shareholders of the Company through postal ballot process. |
| 3 | Brief profile (in case of appointment) | Attached with this intimation |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Dr. Alpna Hansraj Seth is not related to any of the Director or Key Managerial Personnel of the Company. |
of Dr. Alpna Hansraj Seth
in her career at Biogen, she led oncology R&D which culminated in a successful merger of equals with Idec Pharma to form Biogen Idec.
She was instrumental in establishing Biogen's strategic expansion in Asia as a founding Managing Director in India with its HQ
in Gurgaon, and then returning to Biogen's global HQ in the US to lead the launch of its largest multibillion-dollar neurology
drug franchise world-wide. In 2014 as Senior Vice President, she moved to Europe to spearhead Biogen's foray into biosimilars with
the rapid creation of one of the fastest growing biosimilars businesses in the industry.
with a deep and broad industry expertise in biopharma, Dr. Alpna's experience includes health care and life sciences tools, industrial
biotechnology, diagnostics, and management consulting. In addition to North America, she has lived and worked in Asia and in Europe.
Dr. Alpna has a track-record of creating and leading new businesses across therapeutic areas and modalities including biologics (novel
and biosimilars), small molecules, gene therapy and RNA-based therapeutics.
addition, Dr. Alpna brings extensive corporate governance and strategic oversight experience as a member of the Board of Directors of
large publicly listed multinationals and VC-funded private biotech companies. Dr. Alpna currently serves as an independent Director on
the boards of three public (NASDAQ listed) companies- Seagen, Bio-Techne and Keros Therapeutics.
Alpna received a Ph.D. in biochemistry and molecular biology from University of Massachusetts Medical School and conducted her post-doctoral
research at Harvard University in immunology and structural biology, both as a Howard Hughes Medical Institute Fellow. She is also a
graduate of Harvard Business School's Advanced Management Program.